These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6178592)

  • 81. Differences in non-MHC restricted cytotoxic activities of human peripheral blood lymphocytes after transfusion with allogeneic leukocytes or platelets possessing class I and/or class II MHC molecules.
    Pócsik E; Mihalik R; Réti M; Gyódi E; Pálóczi K; Mayer K; Kassai M; Herold M; Huber C; Petrányi GG
    Immunobiology; 1990 Dec; 182(1):22-31. PubMed ID: 1983002
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Single agent therapy of interferon for brain tumours: correlation between natural killer activity and clinical course.
    Otsuka S; Handa H; Yamashita J; Suda K; Takeuchi J
    Acta Neurochir (Wien); 1984; 73(1-2):13-23. PubMed ID: 6208758
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Interferon-induced resistance of fibroblasts to cytolysis mediated by natural killer cells: specificity and mechanism.
    Trinchieri G; Granato D; Perussia B
    J Immunol; 1981 Jan; 126(1):335-40. PubMed ID: 7451975
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Relationship between natural killer (NK) cells and interferon (IFN) alpha-producing cells in human peripheral blood. Studies with a monoclonal antibody with specificity for human natural killer cells.
    Abb J; Abb H; Deinhardt F
    Immunobiology; 1984 Oct; 167(4):359-64. PubMed ID: 6510947
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Comparison of the effects of interferon of various types on the cytotoxic activity of NK cells].
    Dozono H; Terashima Y; Saijo N
    Gan No Rinsho; 1986 Oct; 32(12):1557-60. PubMed ID: 3783981
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Variability in the expression of a beta 2-microglobulin epitope on hepatocytes in chronic type C hepatitis on treatment with interferon.
    García-Buey L; López-Botet M; García-Sánchez A; Balboa MA; Aramburu J; García-Monzón C; Acevedo A; Moreno-Otero R
    Hepatology; 1993 Mar; 17(3):372-82. PubMed ID: 7680330
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Interferon therapy in multiple myeloma: failure of human fibroblast interferon administration to the course of light chain disease.
    Billiau A; Bloemmen J; Bogaerts M; Claeys H; Van Damme J; De Ley M; de Somer P; Drochmans A; Heremans H; Kriel A; Schetz J; Tricot G; Vermylen C; Verwilghen R; Waer M
    Eur J Cancer Clin Oncol; 1981 Aug; 17(8):875-82. PubMed ID: 6173221
    [No Abstract]   [Full Text] [Related]  

  • 88. Enzymatic modifications of human fibroblast and leukocyte interferons.
    Otto MJ; Sedmak JJ; Grossberg SE
    J Virol; 1980 Aug; 35(2):390-9. PubMed ID: 6160260
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacokinetic comparison of leukocyte and Escherichia coli-derived human interferon type alpha.
    Sarkar FH
    Antiviral Res; 1982 May; 2(1-2):103-6. PubMed ID: 6179467
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.
    Villa E; Trande P; Grottola A; Buttafoco P; Rebecchi AM; Stroffolini T; Callea F; Merighi A; Camellini L; Zoboli P; Cosenza R; Miglioli L; Loria P; Iori R; Carulli N; Manenti F
    Dig Dis Sci; 1996 Jun; 41(6):1241-7. PubMed ID: 8654159
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The clinical application of fibroblast interferon--an overview.
    Billiau A
    Med Oncol Tumor Pharmacother; 1984; 1(2):87-96. PubMed ID: 6400034
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo.
    Rhodes J; Jones DH; Bleehen NM
    Clin Exp Immunol; 1983 Sep; 53(3):739-43. PubMed ID: 6311468
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Low doses of interferon alpha result in more effective clinical natural killer cell activation.
    Edwards BS; Merritt JA; Fuhlbrigge RC; Borden EC
    J Clin Invest; 1985 Jun; 75(6):1908-13. PubMed ID: 4008643
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The interferon system as a basis for antiviral therapy or prophylaxis.
    Billiau A
    Antiviral Res; 1985; Suppl 1():131-40. PubMed ID: 3936410
    [No Abstract]   [Full Text] [Related]  

  • 95. A phase I trial of recombinant gamma interferon in patients with cancer.
    Foon KA; Sherwin SA; Abrams PG; Stevenson HC; Holmes P; Maluish AE; Oldham RK; Herberman RB
    Cancer Immunol Immunother; 1985; 20(3):193-7. PubMed ID: 3933818
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy.
    Tentori L; Fuggetta MP; D'Atri S; Aquino A; Nunziata C; Roselli M; Ballatore P; Bonmassar E; De Vecchis L
    Cancer Immunol Immunother; 1987; 24(1):86-91. PubMed ID: 3815421
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pyrogenic and haematological effects of the interferon-inducing 22K factor (interleukin 1 beta) from human leukocytes.
    van Damme J; Opdenakker G; de Ley M; Heremans H; Billiau A
    Clin Exp Immunol; 1986 Nov; 66(2):303-11. PubMed ID: 3493097
    [TBL] [Abstract][Full Text] [Related]  

  • 98. IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.
    Hokland M; Basse P; Justesen J; Hokland P
    Cancer Metastasis Rev; 1988 Nov; 7(3):193-207. PubMed ID: 2465842
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.
    Wejstål R; Norkrans G; Weiland O; Schvarcz R; Fuchs D; Wachter H; Fryden A; Glaumann H
    Clin Exp Immunol; 1992 Mar; 87(3):340-5. PubMed ID: 1544220
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients.
    Lucero MA; Magdelenat H; Fridman WH; Pouillart P; Billardon C; Billiau A; Cantell K; Falcoff E
    Eur J Cancer Clin Oncol; 1982 Mar; 18(3):243-51. PubMed ID: 6178592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.